CDER Compliance Director Recused From Most Duties Due To Husband's Promotion
This article was originally published in The Tan Sheet
Executive Summary
The HHS general counsel determines that to prevent potential conflicts of interest, Cynthia Schnedar must no longer handle substantive issues for compliance actions and policy.
You may also be interested in...
CDER’s New Compliance Director Sklamberg Brings Experience On Compounding Issues
Howard Sklamberg, deputy associate commissioner in FDA’s Office of Regulatory Affairs, will take over as director of the Center for Drug Evaluation and Research’s Compliance Office in January; acting compliance director Ilisa Bernstein will resume her role as deputy director.
US FDA’s Califf: Payers Should Ask How They Can Help Answer Clinical Research Questions
Instead of asking why confirmatory trials take so long, the FDA commissioner suggests insurance companies ask what they can do to help answer those questions.
Biosimilar Interchangeable Exclusivity Guidance Still Planned Despite Memo Release, US FDA Says
While many interpretations of the law protecting the first interchangeable biosimilar approved for a reference product are included in a recently released FDA memo, the agency says it has a limited scope.